Despite geopolitical tensions, the US and Chinese biotech industries are highly synergistic. An estimated 80% of US biotech companies use Chinese Contract Research Organizations (CROs) for cheaper and faster R&D. This on-the-ground reality shows a reliance on international partners for core development activities, enabling a more efficient global ecosystem.

Large multinational pharma companies publicly express concern about the threat from China's biopharma sector. Simultaneously, these same companies are investing billions, actively integrating China into the global ecosystem and contradicting their own zero-sum game narrative.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

In stark contrast to the often adversarial U.S. perspective, the European biopharma community increasingly views China as a strategic partner. The focus is not on competition but on integration, leveraging China as a "force multiplier" for global drug development and commercialization, highlighting a significant divergence in geopolitical business strategy.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

A deep philosophical and financial divide exists within the U.S. biopharma industry regarding China. Some leaders, like Ginkgo Bioworks' CEO, advocate for protectionist investment controls to counter Chinese competition. In contrast, others, like RA Capital's Peter Kolchinsky, argue such walls harm global innovation, revealing a core debate often aligned with financial interests.

Despite media narratives of US-China tensions, Enviva's CEO reports a smooth operational experience in the US. Scientific-driven bodies like the FDA accepted their Chinese clinical data, and US-based investigators have been eager to collaborate, suggesting that on-the-ground scientific and patient-focused priorities can override political friction.

The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.

Despite US-China tensions threatening innovation, the likely outcome is 'coopetition'—a blend of competition and collaboration—as global pharmaceutical firms navigate the dual imperatives of advancing innovation and ensuring supply chain resilience.